UVXY NEWS! 67.00 Ultra VIX Short-Term Fut ETF Proshares (UVX

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ultra VIX Short-Term Fut ETF Proshares (UVXY) 67.00 $UVXY

Carnage in the Nasdaq and Russell 2000 Indexes
at The Street - Mon Apr 07, 4:12PM CDT
The selling continued as both the Nasdaq and Russell 2000 have entered into Trend Bearish territory.

DJIA and S&P Finally Succumb to the Nasdaq and Russell 2000
at The Street - Fri Apr 04, 4:12PM CDT
The DJIA and S&P 500 finally see some serious selling pressure.

DJIA, S&P 500 Continue to Outperform Others
at The Street - Thu Apr 03, 4:48PM CDT
The DJIA and the S&P 500 continue to outperform the Nasdaq and Russell 2000 on a daily basis. This is not good news for the intermediate term.

Another All-Time Bubble High for the S&P 500
at The Street - Wed Apr 02, 4:38PM CDT
The S&P 500 set another all-time bubble high as the short hedge funds scrambled to buy the high after selling the low last week.

Volatility ETFs Crash as Market Fears Drop - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 1:00PM CST
Thanks to declining worries about the market, volatility ETNs have lost all of their 2014 momentum.

Volatility ETFs Skyrocket on Broad Market Weakness - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Mon Feb 03, 9:00AM CST
Inside the incredible run in the volatility ETF market over the past ten days.

What This Indicator Is Saying About the S&P 500
Lee Samaha, The Motley Fool - Motley Fool - Mon Dec 30, 6:00PM CST
There is no such thing as a magic indicator that will tell you when to buy and sell the S&P 500 , and we Fools do not recommend timing the market. However, Foolish investors can use the following indicator to decide whether to be fearful of a...

The Two Month VIX Cycle
Chad Karnes - ETFG - Fri Nov 15, 7:37PM CST
Buying the VIX is a great way to hedge your portfolio, if you can get the timing right. Luckily, the VIX has provided us some excellent technical clues that we can combine with the uncertainty from Washington to come up with some great VIX trades.

Are VIX Traders Riding the Wrong Roller Coaster?
Ron DeLegge - ETFG - Thu Oct 24, 9:58PM CDT
We highlight the performance discrepancies between the VIX and VIX ETPs and why traders need to understand the difference.

American Default Worries are Great News for These ETFs - ETF News And Commentary
Eric Dutram - ZACKS - Wed Oct 16, 9:00AM CDT
Altohugh many stocks and ETFs are down on Washington D.C. issues, these ETFs have been strong performers.

Is a Fearless Stock Market Cause for Concern?
Chad Karnes - ETFG - Wed Aug 14, 7:38PM CDT
The VIX can often signal a peak in stock market prices. By flipping it, it will typically move up and down along with the market and can sometimes be easier to help identify major market turning points.

Volatility Is On My Mind - Analyst Blog
Nick Kalivas - Zacks Investment Research - Fri Aug 02, 3:45PM CDT
S&P 500 30 day historical volatility is getting low. It???s worth watching.

A Common Sense View for Investing in Stocks
Chad Karnes - ETFG - Tue Jun 18, 3:31PM CDT
A little common sense can go a long way. After a 4 year non-stop market rally, long-term investors really should take a step back and wonder if they are just chasing returns or actually making good purchase decisions.

Unemployment: Is Resilience an Illusion? - Analyst Blog
Abhijit Ghosh - Zacks Investment Research - Thu May 16, 12:58PM CDT
After sinking to a five-year low last week, jobless claims have now jumped to a seasonally adjusted level of 360,000.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 255

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 266

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 113

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 59

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Flora Growth Corp Sees 6% Surge in After-Hours Performance

Updated Category News Views 87

A Surge in After-Hours Trading for Flora Growth Corp Flora Growth Corp. (NASDAQ: FLGC) recently demonstrated significant volatility by surging 5.98% to $10.55 during after-hours trading. This movement came not long after closing at $9.96, which marked an increase of 3.59% earlier that day. Insights from Recent SEC Filing Regulation A Filing In a notable move, Flora Growth...

Continue Reading
Qubs Introduces Qubitunes, A New Interactive Audio Experience

Updated Category News Views 205

Qubs Launches Qubitunes for Creative Play Qubs has unveiled an exciting new product, Qubitunes, which has already won the 'Top Toy' award in the startup category at a prestigious Toy Fair. This innovative toy is set to transform playtime for children by offering a unique platform where they can express their creativity and dive into their own audio storytelling...

Continue Reading
Asyad Group's Expert Transport of Heavy Cryogenic Tank

Updated Category News Views 126

Asyad Group's Successful Transport of Cryogenic Tank Asyad Group has recently completed a remarkable international transport operation, successfully moving a 115 metric ton pressurized cryogenic tank from Northern India to a major destination in Saudi Arabia. This endeavor highlights the Group's expertise in cross-border logistics. A Journey of Precision The transport...

Continue Reading
Famous Toastery Launches Holiday Fundraising Efforts

Updated Category News Views 134

Famous Toastery's Compassionate Campaign for Local Communities The Famous Toastery, known for its delightful breakfast and brunch offerings, is stepping up this holiday season with a noble initiative aimed at fighting hunger. This renowned franchise is collaborating with Feeding the Carolinas, encouraging guests to make donations that will significantly impact individuals...

Continue Reading
Jiayin Group's Upcoming Earnings Call Set for November 25, 2025

Updated Category News Views 190

Jiayin Group Inc. Announces Q3 2025 Financial Results Release Jiayin Group Inc. (NASDAQ: JFIN), a prominent fintech platform in China, has shared significant news that it will unveil its unaudited financial outcomes for the third quarter of 2025. This crucial announcement is set to occur before the U.S. markets open on November 25, 2025. The anticipation surrounding these...

Continue Reading